# Lifespan Vision Ventures Leads Violet Therapeutics' $4.75M Seed Extension Financing

- Link: https://www.thailand-business-news.com/pr-news/lifespan-vision-ventures-leads-violet-therapeutics-4-75m-seed-extension-financing
- Published: 2026-05-19T00:03:00+07:00
- Author: PR Newswire

|   |

NORWALK, Conn., May 19, 2026 /PRNewswire/ — Lifespan Vision Ventures (LVV), an investment
firm focused on therapeutics that improve human healthspan, today announced that
it has led Violet Therapeutics’ $4.75 million seed extension financing, with participation
from Dementia Discovery Fund, UTEC, Ono Venture Investment, and Mass General Brigham
Ventures.

Violet Therapeutics is a preclinical-stage biotechnology company developing first-
in-class therapies for neurodegenerative disease by mapping disease-relevant cell-
to-cell signaling interactions in the brain. The company’s proprietary CONNECT platform
is designed to identify therapeutically actionable signaling pathways that drive
neuroinflammation, neurodegeneration, and synaptic loss.

Synaptic loss is one of the strongest predictors of cognitive decline in Alzheimer’s
disease and other neurodegenerative conditions, and Violet’s lead program is designed
to address this core pathology through glial-mediated synaptic preservation and 
repair. "Preserving cognitive function is one of the most important challenges in
aging biology, and Violet is approaching that challenge from a uniquely actionable
angle," said Altar Munis, Associate at Lifespan Vision Ventures. "The company’s 
CONNECT platform gives it a systematic way to uncover how glial signaling contributes
to synaptic dysfunction, with EphB3 representing a strong first step toward therapies
that may protect brain health across aging and neurodegenerative disease."

"We are pleased to welcome LVV as the lead investor in this extension round. LVV
brings deep sector expertise in technologies that will impact diseases of aging 
and cognition. Likewise, their addition to the board adds valuable perspective as
we continue to advance our EphB3 program towards the clinic and to develop our CONNECT
discovery platform," said Meredith Fisher, Partner at Mass General Brigham Ventures
and CEO of Violet.

Proceeds from the financing will support advancement of Violet’s lead small molecule
program targeting EphB3 through key IND-enabling activities. EphB3, a receptor tyrosine
kinase implicated in microglia-astrocyte signaling, emerged directly from Violet’s
CONNECT platform and represents the company’s first therapeutic target generated
from its cellular connectome approach.

**About Lifespan Vision Ventures**

Lifespan Vision Ventures is a global venture capital firm investing in early-stage
biotechnology companies developing breakthrough technologies to prevent and treat
age-related diseases. The firm partners with visionary founders advancing science-
driven solutions that promote healthy aging and extend human healthspan.

**Contact:** [info@lifespanvision.com](https://www.thailand-business-news.com/pr-news/info@lifespanvision.com)

**About Violet TherapeuticsViolet Therapeutics is a preclinical-stage biotechnology
company developing first-in-class therapies for neurodegenerative disease by mapping
disease-relevant cell-to-cell signaling interactions in the brain. The company’s
proprietary CONNECT platform enables discovery of novel targets emerging from cellular
interaction networks rather than genetic association alone, supporting the development
of a pipeline of small-molecule therapeutics addressing neuroinflammation and related
CNS pathologies.

For more information, visit [www.violettx.com](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4690870-1&h=1333769185&u=http%3A%2F%2Fwww.violettx.com%2F&a=www.violettx.com)

Media contact: 
Meredith Fisher, CEO[meredith@violet-tx.com](https://www.thailand-business-news.com/pr-news/meredith@violet-tx.com)

 

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Lifespan Vision Ventures Leads Violet Therapeutics' $4.75M Seed Extension Financing ](http://www.prnasia.com/story/archive/4961876_AE61876_0?rand=184833)